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The Epstein-Barr virus (EBV) is found in a variety of
tumors whose incidence greatly varies around the
world. A poorly explored hypothesis is that particular
EBV strains account for this phenomenon. We report
that M81, a virus isolated from a Chinese patient with
nasopharyngeal carcinoma (NPC), shows remark-
able similarity to other NPC viruses but is divergent
from all other known strains. M81 exhibited a
reversed tropism relative to common strains with a
reduced ability to infect B cells and a high propensity
to infect epithelial cells, which is in agreement with its
isolation from carcinomas. M81 spontaneously repli-
cated in B cells in vitro and in vivo at unusually high
levels, in line with the enhanced viral replication
observed in NPC patients. Spontaneous replication
and epitheliotropism could be partly ascribed to
polymorphisms within viral proteins. We suggest
considering M81 and its closely related isolates as
an EBV subtype with enhanced pathogenic potential.INTRODUCTION
The Epstein-Barr virus (EBV) chronically infects the largemajority
of the world population, usually without clinical consequences.
However, in a minority of individuals, EBV infection is associated
with the development of a variety of diseases, ranging from
infectious mononucleosis (IM) syndromes to various cancers
(Rickinson and Kieff, 2007). Although the virus homogeneously
targets populations from all geographic areas, the incidence of
the diseases it causes can vary drastically (Chang et al., 2009).
While IM is common in Western populations, Burkitt lymphoma
(BL) is endemic in equatorial Africa and nasopharyngeal carci-
noma (NPC) is one of the most common tumors encountered458 Cell Reports 5, 458–470, October 31, 2013 ª2013 The Authorsin Southeast Asia. What causes these variations in disease inci-
dence is unclear, although the age at which EBV infection takes
place, environmental factors such as food contaminations with
nitrosamines and phorbol esters or smoking, and concurrent dis-
eases such as malaria are all known to play an important role
(Hsu and Glaser, 2000; Hsu et al., 2009; Jia and Qin, 2012; Yu
and Yuan, 2002). The genetic background of the affected individ-
uals has also been invoked to explain this puzzling phenomenon
(Hildesheim et al., 1997; Levine et al., 1992; Li et al., 2009; Lu
et al., 1990; Ung et al., 1999). Another nonexclusive hypothesis
is that the occurrence of these diseases reflects the existence
of multiple virus subtypes that are endowed with different prop-
erties but are found only in restricted geographic areas. Strong
evidence for genetic polymorphisms between EBV isolates has
been garnered frompartial or total sequencing ofmultiple viruses
from all over the world. However, it has not been easy to appre-
ciate the consequences of this genetic heterogeneity in terms of
viral functions, particularly because of the difficulty in assessing
the biological properties of viruses that carry these various poly-
morphisms. Here, we report an attempt at linking the genetic
polymorphisms found in these viruses with their phenotypic
traits. We have cloned and fully sequenced M81, a virus isolated
from an NPC that developed in a Chinese individual (Desgranges
et al., 1976, 1979). We found that M81 is highly similar to viruses
isolated from NPCs and that it profoundly differs in terms of virus
infection and replication from extensively characterized Western
strains. These observations demonstrate the existence of
distinct EBV subtypes and suggest that the unusual properties
evinced byM81-type viruses are likely to explain their tight asso-
ciation with NPC.
RESULTS
The M81 Strain Is Representative of Viruses that Infect
NPC Tissues
In an attempt to study the genotype and phenotype of the
EBV strain M81, we cloned its genome onto the F-factor-based
Figure 1. Generation and Characterization
of the Recombinant M81 EBV Genome
(A) Genomic maps of the recombinant M81 (rM81)
and B95-8 (rB95-8) viruses. The rM81 was gener-
ated from the marmoset M81 cell line by inserting
an F-factor plasmid coupled to the hygromycin
resistance cassette between the terminal repeats
(TR). IR, internal repeats.
(B) Minipreparations of DNA from the rM81 and the
rB95-8 genome were cleaved with the restriction
enzyme BamHI.
(C and D) Distance trees based on available EBV
genome sequences at the DNA (C) and protein
level (D) show that the M81 strain is closely related
to GD2 and HKNPC1, two EBV strains found in
NPC tumor cells.
See also Figures S1 and S2.replicon in E. coli as described before (Delecluse et al., 1998).
The F-factor-based replicon was recombined into the terminal
repeats and therefore did not disrupt coding regions (Figure 1A).
The structure of the recombinant M81 strain genome (rM81) was
assessed by restriction enzyme analysis (Figure 1B). This anal-
ysis revealed that the M81 genome is larger than B95-8 but
also that multiple genomic polymorphisms exist between the
two strains, as the length of the fragments was frequently
different. In parallel, we completely sequenced the rM81 genome
to allow its classification among sequenced EBV strains as well
as its polymorphisms. To this end, we built genetic distance trees
based on the published type 2A EBV genomes that include
B95-8, one of the prototypical laboratory strains (Baer et al.,
1984), the Akata and the Mutu viruses that were isolated from
BLs that respectively developed in a Japanese and an African
patient (Gregory et al., 1990; Lin et al., 2013; Takada et al.,
1991), as well as GD1, GD2, and HKNPC1, three viruses that
were either rescued from Chinese NPC patients with NPC or
directly isolated from the tumors (Kwok et al., 2012; Liu et al.,
2011; Zeng et al., 2005). The nonsequenced gene regions of
the HKNPC1 genome (6,479 nt; coordinates 35,273–36,144,
38,194–40,624, and 139,951–143,126) and the region corre-Cell Reports 5, 458–470sponding to the BART deletion in B95-8
could not be included into the analysis.
We further trimmed the terminal and
BamHI-W repeats to have the same num-
ber of repetitions across all sequences.
We found that M81 is closely related
to the other NPC strains but much
more distant from the other strains (Fig-
ures 1C and 1D). In particular, M81 and
HKNPC1 showed only 0.2% divergence
at the DNA level (Figure 1C). This is impor-
tant because HKNPC1 was directly
sequenced from an NPC biopsy spec-
imen and was therefore present in the
tumor cells (Kwok et al., 2012). We refined
our analysis by comparing 50 viral protein
sequences among these strains and
found that M81 is 99.9% homologous toHKNPC1 but much more distant from B95-8 (Figure 1D). Addi-
tional distance trees are shown in Figure S1 for key EBV proteins
such as LMP1, EBNA2, BZLF1, and BLLF1. We conclude that
M81 is a valid representative of the EBV strains that are found
in Chinese NPC. We then attempted to extend our comparisons
to EBV isolates found in the general population. Numerous
studies have compared the sequence of the LMP1 gene and of
the BZLF1 gene and its promoter among isolates worldwide
(see Table S1). This has led to the recognition of an EBV variant
preferentially, but not exclusively, found in Asian countries. We
found that M81 belongs to this variant whose frequency in-
creases from North to South China and that is preferentially
found in NPC (Table S1). These results suggest that rM81 can
be used to study the properties of this variant isolate. How-
ever, the limited number of genes on which the recognition
of the variant is based may not account for the complexity pro-
vided by thewhole virus, and it ismore likely that the variant cate-
gory of EBV comprises multiple virus isolates with variation in
properties.
We then stably introduced the rM81 DNA into human embry-
onic kidney 293 (HEK293) cells to generate a virus producer
cell line. The integrity of the EBV genome in the stably transfected, October 31, 2013 ª2013 The Authors 459
Figure 2. M81 Displays a Reduced Tropism
for B Cells but M81 and B95-8 Do Not Differ
in Their Transforming Potential
(A) Primary human B cells were exposed to the
same number of viral genomes and infected cells
were stained for EBNA2 3 dpi. Values are repre-
sented as mean ± SD (B) rM81 and rB95-8 present
in infectious supernatants from induced producer
cells were pelleted by ultracentrifugation and
analyzed by transmission electron microscopy.
Bar: 200 nm.
(C) Southern blot analysis of BamHI-cleaved
genomic DNA isolated from LCLs generated with
B cells from three different donors after infection
with rB95-8 or rM81. The DNAs were hybridized
with a probe specific for the terminal repeats
(upper panel) or for the F-plasmid (lower panel).
p, polyclonal culture; m, monoclonal culture.
(D) Western blot analysis performed with anti-
bodies specific to the viral glycoproteins gp350/
220 and gp110 on proteins extracted from lytically
induced producer cell lines or their pelleted
supernatants. An antibody specific to the tegument
protein BNRF1 was used as a loading control.
(E) Alignment of the BLLF1 gene that encodes
gp350 from either M81 or B95-8. Three major
deletions in M81 BLLF1 are shown.
(F) A transformation assay with rM81 or rB95-8
was performed with a similar number of EBNA2
infected cells per well. The transformation effi-
ciency was analyzed by determining the percent-
age of outgrowing colonies 30 dpi.
Values represent mean ± SD. See also Figures S3
and S4.HEK293 clones was confirmed by shuttling the rM81 episomes
they contained into E. coli cells from which restriction analyses
could be performed (Figure S2). We then activated virus produc-
tion by transfecting BZLF1 into the producer cells and used the
generated viruses to determine rM81’s phenotypic traits.
M81 Has a Reduced B Cell Tropism Relative to B95-8,
but M81 Efficiently Transforms Infected B Cells
We began assessing M81’s tropism by infecting resting primary
peripheral blood B cells. Three days after exposure to superna-
tants containing the same genome copy numbers of rM81 or
rB95-8, the B cells were stained with an antibody specific to
the viral nuclear antigen EBNA2. This assay revealed that the
number of infected cells after incubation with rM81 was between
five and ten times lower than after exposure to rB95-8 (Figure 2A),
although viruses in pelleted supernatants from both producer
cell lines were visible in both cases and evinced similar morpho-460 Cell Reports 5, 458–470, October 31, 2013 ª2013 The Authorslogical traits (Figure 2B). Similar results
were obtained with M81 viruses collected
from the original marmoset M81 LCL,
demonstrating that rM81’s reduced B
cell tropism was not due to a cloning arti-
fact (Figure S3). Importantly, we found
that B cells infected with rM81 exclusively
carried viral episomes that were devoid ofthe F-plasmid but conserved a large number of terminal repeats
(Figure 2C). This can be explained by excision of the F-plasmid
through recombination of the highly homologous terminal re-
peats that flank it, as previously described for another recombi-
nant herpesvirus genome (Zhou et al., 2010). We then wished to
determine whether these results could be explained by a
reduced ability of M81 to bind to B cells. We exposed B cells
to supernatants containing the same genome equivalents of
rM81 or rB95-8, extensively washed the cells, and determined
by quantitative PCR (qPCR) the number of viruses bound to
the surface of the cells. We found that rM81 and rB95-8 had a
very similar binding efficiency to B cells (data not shown).
EBV infects B cells through interaction of viral glycoproteins
with cellular receptors (Connolly et al., 2011; Hutt-Fletcher,
2007). Among these glycoproteins, gp350 and gp110 play an
important role for binding to and for fusion with the B cell mem-
branes. Therefore, we assessed the amount of gp350 inM81 and
B95-8 virions by western blotting using specific antibodies. The
results of these assays, shown in Figure 2D, revealed that gp350
is expressed in producer cell lines and free virions at approxi-
mately the same level. However, western blotting showed that
M81 gp350 migrates quicker than its homolog in B95-8 and
that M81 gp220, the spliced form of gp350, is more abundant
relative to its B95-8 homolog. Analysis of M81’s sequence re-
vealed multiple deletions in the BLLF1 gene that encodes this
protein relative to B95-8 that could account for the difference
in protein size (Figure 2E). Therefore, we complemented a
rB95-8 devoid of the BLLF1 gene with an expression plasmid
carrying the BLLF1 gene encoded by M81 or B95-8 and
assessed its ability to bind to and to infect B cells. Complemen-
tation significantly enhanced binding and infection of B cells but
we could not identify any difference after complementation with
either type of BLLF1 (data not shown). Thus, M81 demonstrates
a reduced B cell tropism, which, however, is not caused by its
altered gp350 sequence.
We then determined the ability of rM81 to transform B cells.
Resting B cells were exposed to rB95-8 or rM81 at multiplicities
of infection (MOIs) that gave rise to the same number of EBNA2-
positive cells. Infected B cells were seeded at low cell density in
96-well plates, and we counted the number of outgrowing
colonies 30 days postinfection (dpi). We found that the number
of colonies, and therefore the ability to initiate B cell transforma-
tion, was similar with both viruses (Figure 2F). Similar experi-
ments performed with nonrecombinant viruses had the same
outcome (Figure S3).
B Cells and 293 Cells Infected by M81 Evince Enhanced
Lytic Replication In Vitro
We quantified virus production in the 293/rM81 producer cell
lines using qPCR with primers and probes specific for the non-
repetitive sequence that encodes the viral DNA polymerase.
We found that all studied clones produced virus at high levels,
on average five times higher than 293/rB95-8 cells that carry
the B95-8 recombinant genome, although the number of repli-
cating cells as determined by gp350 staining was identical (8.3
versus 7.7%, respectively) (Figure 3A; data not shown). This
more efficient virus production in 293/rM81 does not correlate
with a higher EBV copy number within the stably transfected
293 cells (Figure 3B). We then studied virus production in LCLs
established from 18 healthy donors of European or Asian
descent with the rM81, rB95-8, or rAkata EBV strains. Surpris-
ingly, all LCLs generated with rM81, but none of those infected
with rB95-8 or with rAkata, showed evidence of spontaneous
lytic replication. This included robust expression of the immedi-
ate early protein BZLF1 beginning at around 18–20 dpi, expres-
sion of the late structural protein gp350 onmost cells (Figure 3C),
and production of free viruses in the supernatant as defined by
qPCR (Figure 3D). However, the gp350 signals were confined
to the cell surface and only a minority of cells displayed intense
cytoplasmic staining as expected from virus-producing cells.
This staining pattern is most likely due to virus binding to the
surface of nonreplicating B cells. We then monitored virus
replication in LCLs infected with rM81 for more than 3 months
using BZLF1 expression as a readout and found that rM81
LCLs established with different donors undergo a persistentCand robust lytic replication for the whole study period (Figure 3E).
These cells also kept producing gp350 at high levels (data not
shown). Viral DNA replication and production of progeny virus
(Figure 2C) could be validated by a Southern blot assay detecting
newly generated linear viral genomes and by the detection of
newly produced viruses in electron micrographs, both in
lymphoid cells and in the supernatant (Figure 3F). We could
also propagate the infection from B cells to B cells by infecting
resting B cells with supernatants from LCLs generated with
rM81 (data not shown). Importantly, these results could be
repeated with the nonrecombinant M81, demonstrating again
that the cloning procedure was not responsible for rM81’s prop-
erties (data not shown).
Polymorphisms in the BZLF1 Protein Contribute to
Spontaneous Lytic Replication in LCLs Transformed
with rM81
The different outcome after infection of the same B cells with
rB95-8, rAkata, or rM81 prompted us to search for polymor-
phisms between M81 and B95-8. One obvious difference
between M81 and B95-8 is the absence of some of the BART
microRNAs (miRNAs) in the latter. However, most EBV strains
carry these genetic elements and none of them were previously
reported to spontaneously replicate as strongly as M81 (Kieff
and Rickinson, 2007). Indeed, B cells infected with Akata, which
carries all BART miRNAs, showed only weak and transitory lytic
replication (Figure 3C; data not shown). Another obvious candi-
date was BZLF1, the lytic replication master protein (Miller,
1990). Therefore, we constructed a recombinant M81 genome
that lacks the genome fragment that carries the BZLF1 gene.
We infected B cells with this M81/DBZLF1 virus and with a
B95-8/DBZLF1 virus that we previously reported (Feederle
et al., 2000). The resulting LCLs were then stably transfected
with an expression plasmid encoding the M81/BZLF1 or the
B95-8/BZLF1 genes, under the control of a doxycycline-induc-
ible promoter. We found that lytic replication can be efficiently
induced in LCLs transformed by M81/DBZLF1 and comple-
mented by the M81/BZLF1 gene but that this complementation
was much less efficient with B95-8/BZLF1 (Figure 4A). However,
M81/BZLF1 was not better than its B95-8 homolog in its ability to
induce lytic replication in B95-8/DBZLF1 LCLs. We conclude
that polymorphisms in the BZLF1 genes partly explain M81’s
ability to induce lytic replication but that other viral genes play
an important role in the ability of the B cells to support lytic
replication.
We then addressed the possibility that the spontaneous lytic
replication we observed in cells infected with M81 was the result
of a polymorphism in the promoter of BZLF1. Indeed, this region
was previously found to be highly polymorphic, with some poly-
morphisms being typically observed in Chinese strains (Jin et al.,
2010; Luo et al., 2011). Therefore, we constructed an M81 re-
combinant virus in which the BZLF1 gene and its promoter
were exchanged against its homolog from B95-8. Monitoring
of BZLF1 expression in cells infected by this mutant showed
spontaneous expression 21 dpi, as did the wild-type rM81 virus
(Figure 4B). We conclude that the initiation of spontaneous repli-
cation is not due to the differences in the exchanged regions
between B95-8 and M81.ell Reports 5, 458–470, October 31, 2013 ª2013 The Authors 461
Figure 3. Primary Human B Cells Infected with M81 Show Enhanced Lytic Replication
(A) The figure displays the viral titers measured in supernatants of induced rM81 or rB95-8 producer cell lines. Values represent mean ± SD. geq, genome
equivalents.
(B) A Southern blot analysis of genomic DNAs extracted from different producer cell lines was performed with a nonrepetitive EBV-specific probe spanning the
BMRF1 fragment. The intensity of the signals is given with the first signal normalized to one.
(C) LCLs were generated by infecting B cells from the same donor with rM81, rB95-8, or rAkata. These continuously growing cell lines were stained at 44 dpi with
an antibody specific to gp350. Overlayed and inverted pictures are presented.
(D) Viral titers in supernatants from noninduced LCLs transformed with rM81 or rB95-8 were determined by qPCR. The results of this assay are given as genome
equivalents per ml of supernatant. Values represent mean ± SD.
(E) LCLs generated with B cells from 18 independent donors (12 whites, C1-C12; 6 Asian donors, A1-6) were infected with rM81 and monitored for virus pro-
duction for up to 4.5 months. Immunostaining for BZLF1 was used as a readout for spontaneous lytic replication and the percentage of cells positive for this
protein are given. The graph of bars gives the mean ± SD of weakly measurements performed during the indicated period of time in months (m).
(F) Virus production in rM81-transformed LCLs and pelleted supernatants thereof was examined by transmission electron microscopy. Arrows highlight virus
particles. Bar in insets represents 200 nm.
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Figure 4. Polymorphisms within the BZLF1
Protein Encoded by M81 Contribute to the
Strong Lytic Replication Observed in LCLs
Transformed by rM81
(A) LCLs were generated by exposure to rM81/
DBZLF1(M81DZ) or rB95-8/DBZLF1(B95-8DZ) and
were stably transfected with an expression plasmid
encoding the BZLF1 gene encoded by either M81 or
B95-8. These genes are under the control of a
tetracycline-inducible promoter. The ratio of gp350-
positive relative to BZLF1-positive cells 7 days
postdoxycycline treatment is indicated. For each of
the indicated conditions, five experiments were
performed within 2 months postinfection with LCLs
from two donors. The statistical significance of the
findings is given.
(B) LCLs were generated by infection with wild-type
rM81 or with a recombinant rM81 virus that carries
the genesBZLF1 and BRLF1 from B95-8 (B770). The
expression rate of the lytic proteins BZLF1 and
gp350 in these LCLs 30 dpi is indicated. Values
represent mean ± SD of two measurements from
two LCLs generated with two different donors.rM81’s Phenotypic Traits in B Cells Can Be Confirmed in
an Animal Model
We wished to determine whether M81’s properties observed
in vitro after B cell infection could be reproduced in vivo. To
this end, we infected NSG-A2 mice, whose immune system
had been reconstituted with human hematopoietic progenitor
cells (Ra¨mer et al., 2011; White et al., 2012). Altogether, 13
mice were inoculated intraperitoneally with either rB95-8
(7 mice) or rM81 viruses (6 mice) in two independent experi-
ments, monitored for peripheral blood viral load, and then eutha-
nized to record histological evidence of infection and T cell
expansion. Five control mice were mock-treated with PBS. We
found that in all infected mice, EBV infection could be docu-
mented longitudinally by measuring viral loads in the blood and
assaying expression of the EBV-specific noncoding RNAs
EBER in spleen sections at the termination of the experiments
(Figure 5). We also observed CD8+ T cell expansion and upregu-
lation of the activation marker HLA-DR on this T cell subset dur-
ing the course of infection (Figure 5A; data not shown). In one
experiment, we exposed the mice to supernatants containing
the same number of rB95-8 or rM81 genomes. In that case, we
noticed that the number of B95-8-infected B cells in the spleen
was much higher than the number of those infected by rM81 in
all investigatedmice (Figure 5A). In somemice, additional organs
such as the kidney contained EBV-positive cells in rM81-
infected mice. Quantification of EBV copies in the peripheral
blood of infected animals confirmed the increased viral load after
infection with rB95-8 (Figure 5B). These results are in line with
M81’s reduced B cell tropism observed in vitro (see Figure 2A).
In another experiment, we inoculated the mice with virus doses
of either rM81 or rB95-8 that gave rise to the same number of
infected B cells in vitro, as assessed by an EBNA2-specific stain-
ing 3 dpi. In that case, similar numbers of EBV-positive B cells
were visible in the spleen of animals infected with either type of
virus (Figure 5C). We also found rM81- and B95-8-infected
B cells in the mesenteric lymph nodes in comparable numbers
(Figure 5C). However, the viral load in the blood became muchChigher after infection with rM81 4 weeks postinfection (Fig-
ure 5D). These results suggested either that a larger number of
infected B cells circulated in the blood after infection with
rM81, or that a high degree of lytic replication was taking place
in the tissues of infected animals. We therefore stained tissues
from infected mice with antibodies specific to the early and
late replication proteins BZLF1 and gp350. In all cases, mice in-
fected with rM81 carried many more B cells undergoing lytic
replication than rB95-8 infected animals (Figure 5E). Indeed,
numerous cells expressed the BZLF1 or the gp350 lytic proteins
after rM81 infection in vivo (Figure 5E). This was particularly pro-
nounced in the second experiment after inoculation of rM81 at
higher doses (Figure 5E). All mice infected with rM81, either at
low or high doses, showed evidence of lytic replication in tissues
that carried EBV-infected cells. In contrast, we could not find any
unambiguously gp350-positive B cells in any of themice infected
with rB95-8, although a few BZLF1-positive B cells were visible
in the spleen of one mouse (Figure 5E). We conclude that rM81
leads to virus replication in infected B cells in vivo even in the
presence of human immune system activation.
Enhanced Tropism for Epithelial Cells
The isolation of M81 from an NPC implies that this viral strain has
the ability to infect epithelial cells. We and others have previously
found that EBV strains generally have a veryweak tropism for pri-
mary epithelial cells with infection rates of less than a few cells
per thousand, except if viruses are forced to express high
amounts of gp110 and highly differentiated epithelial cells are in-
fected (Feederle et al., 2007; Shannon-Lowe and Rowe, 2011;
Shannon-Lowe et al., 2006). We exposed primary epithelial cul-
tures (pEC) from the epithelium that covers the sphenoidal sinus,
because this mucosa shares many histological features with the
nasopharynx epithelium. We previously showed that resting B
cells can be used as virus carriers for epithelial cell transfer infec-
tion with viruses that incorporated large amounts of gp110 into
the virus envelope (Shannon-Lowe et al., 2006). Therefore, we
performed cell-free as well as transfer infections with pECs usingell Reports 5, 458–470, October 31, 2013 ª2013 The Authors 463
Figure 5. Elevated Lytic EBV Replication in M81-Infected Mice with Reconstituted Human Immune System Components
(A) The pictures show an in situ hybridization with an EBER-specific probe performed on histological sections from the spleens of animals exposed to the same
number of genomes from either rB95-8 or rM81 or mock-infected with PBS. These sections were also stained with an antibody specific to CD8.
(legend continued on next page)
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100 rM81 or rB95-8 genome equivalents per target cell and
stained treated cells for keratin and for EBER expression (Figures
6A and 6B).We found that all infected cells after transfer infection
were keratin positive and thus infected epithelial cells. The re-
sults of both types of infections are presented in Figure 6C and
show that cell-free rB95-8 can hardly or not at all infect pECs
at an intermediate (passage 6) to late (passage 9) passaging
number, which corresponds to a intermediate differentiation
state (Feederle et al., 2007). In contrast, we observed rates of
infection that ranged between 3% and 7% after infection with
cell-free rM81. Higher infection rates, ranging from 4% to 26%,
were obtained after transfer infection with rM81, but transfer
infection with rB95-8 remained inefficient in all performed exper-
iments (Figure 6C). We have previously shown that the glycopro-
tein gp110 is important for infecting primary epithelial cells and
that B95-8 contains low amounts of this protein (Neuhierl et al.,
2002). Therefore, we performed a western blot analysis for
gp110 and found that this protein was expressed at higher levels
in the M81 producer cells and in the released virions than in their
B95-8 counterparts (Figure 2D; Figure S4).
Therefore, we repeated these experiments with viruses ob-
tained from producer cell lines complemented with a BALF4
expression plasmid to increase gp110’s concentration in the pro-
duced viruses and found that the rate of cell-free infection
increased for both rB95-8 and rM81, although the enhancing
effect was much more pronounced for the latter viruses (Fig-
ure 6D). Transfer infection with these gp110-complemented
viruses had little influence on the outcome of infection; infections
with rB95-8 remained essentially negative while those with rM81
were concordant with experiments performed with noncomple-
mented viruses. We then tested whether complementation with
gp110 from M81 was more efficient than those with gp110 from
B95-8 by complementing virus-producing cell lines with either
source of protein. We found that complementation with gp110
from M81 was more efficient relative to complementation with
gp110 from B95-8 (Figure 6E). We conclude that polymorphisms
within gp110 and its expression level partly explain M81’s strong
epitheliotropism but other factors remain to be discovered.
We then studied the outcome of infection in epithelial cell and
found that many infected cells expressed BZLF1 (Figure 6F). A
subset of these also expressed gp350 and produced viruses
visible in electron microscopy, demonstrating that infected cells
complete lytic replication (Figure 6G). Thus, M81 infects epithelial
cellsmuchmoreefficiently thanB95-8 andalso establishes spon-
taneous lytic replication in a subset of infected epithelial cells.
DISCUSSION
This study reports an extensive comparative characterization of
a virus isolated in a NPC developed by a Chinese patient and(B) Dynamics of virus load in the peripheral blood of mice infected under conditi
higher than M81 virus load at week 5 (P value is 0.0009).
(C) Reconstitutedmice were exposed to viral titers that lead to the infection of the
hybridization with an EBER-specific probe was performed on splenic tissues and
(D) Dynamics of virus load in the peripheral blood of infected mice infected under
virus load at week 5 (P value is < 0.0001).
(E) Immunostains for BZLF1 and gp350 were performed on tissues of mice infec
Chow this virus differs from viruses isolated in other parts of the
world. Although M81 and B95-8 can both infect epithelial cells,
the first strain is predominantly epitheliotropic and the second
B lymphotropic. We identified the abundance of gp110 as an
important factor in the ability of M81 to infect epithelial cells.
Nevertheless, other viral proteins are evidently implicated in
this viral function. We previously reported that B95-8 comple-
mented with gp110 can infect differentiated primary epithelial
cells with high efficiency (Feederle et al., 2007). M81 fundamen-
tally differs from B95-8 in that it infects epithelial cells at interme-
diate passage number and differentiation stage in the absence of
any complementation and with a much higher efficiency. Telo-
merase-immortalized cell lines established from epithelial cells
of the nasopharynx that carry genetic abnormalities such as
the loss of p16 have been found to be more sensitive to EBV
infection (Tsang et al., 2010). These observations could explain
the difficulty encountered by many groups to infect normal
epithelial cells. However, a more recent paper from the same
group made clear that p16 downregulation or Cyclin D upregula-
tion facilitates virus persistence rather than virus infection (Tsang
et al., 2012). These data concur with our observations that the
viral subtype rather than the chromosomal integrity determines
the efficiency of infection. Spontaneous lytic replication in
LCLs is in the large majority of cases transitory and limited in in-
tensity (Kieff and Rickinson, 2007). In contrast, we see extensive
late protein and virus production in all types of cells infected with
rM81. Interestingly, the only report of spontaneous lytic replica-
tion in LCLs generated with adult primary B cells was after infec-
tion with ABA, a virus isolated from an NPC that developed in an
African patient (Crawford et al., 1979). We found that the
increased and sustained lytic replication in B cells infected by
M81 is partly due to polymorphisms within the BZLF1 protein
but that other so-far-unknown genetic elements have a strong in-
fluence on this crucial viral function. In contrast, polymorphisms
within BZLF1’s promoter that have been previously described do
not seem to play an important role in M81’s ability to spontane-
ously initiate replication. Here again, other unknown genetic
elements that governM81’s ability to replicate remain to be iden-
tified. Importantly, mice carrying reconstituted human immune
system components also displayed high levels of lytic replication
after infection with rM81, irrespective of the overall viral loads
and the numbers of EBV-infected B cells they carry. Further
studies need to determine whether the observed T cell expan-
sion after rM81 infection that is presumably driven by lytic EBV
antigens provides protection against viral replication, as has
been previously shown for rB95-8 infection with a higher fre-
quency of latent over lytic EBV infection (Strowig et al., 2009).
M81 was isolated in a geographic area where NPC occurs at
high incidence and this virus is genetically very close to other
viruses present in NPC cells. Patients with NPC carry virusesons described in (A); rB95-8 viral load in the peripheral blood was significantly
same number of B cells, as defined by EBNA2 staining, or mock infected. In situ
on mesenteric lymph nodes tissues.
conditions described in (C); rM81 viral load was significantly higher than rB95-8
ted with rM81 or rB95-8.
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Figure 6. rM81 Infects Primary Epithelial Cells with High Efficiency
(A) Primary epithelial cells were infected with rM81 using transfer infection, stained for pan-keratin expression using a specific antibody coupled to fluorescein
isothiocyanate, and counterstained with the nuclear stain Hoechst 33258 (top). The same cells were further evaluated for EBER expression using in situ
hybridization (bottom). Infected cells are indicated by blue arrows.
(B) Primary epithelial cells from the same donor (50p9) were submitted to direct or transfer infection with rM81or rB95-8, with or without complementation with
gp110. Infected cells were identified by EBER in situ hybridization.
(C) The results of infections performed on multiple primary samples at different passages are compiled in this graph (e.g., 67p6 indicates patient number 67,
passage 6). Viruses used in this set of experiments were not complemented with gp110.
(D) The same experiments as in (C) were performed with viruses complemented for gp110 incorporation.
(E) The figure depicts the epitheliotropism of viruses complemented with gp110 encoded byM81 or by B95-8 as determined by EBER expression. Epithelial cells
were infected by transfer infection. Values represent mean ± SD.
(F) Epithelial cells infected with rM81 were immunostained for BZLF1 or gp350 (red signals) and nuclei counterstained with Hoechst 33258 (blue staining).
Infections were repeated three times with cells from one donor.
(G) Primary epithelial cells infected with rM81 were analyzed by transmission electron microscopy. Nuc, nucleus; NM, nuclear membrane; cyt, cytoplasm.
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that are endowed with the ability to replicate at high level in the
absence of overt immunosuppression and that are obviously
epitheliotropic. Indeed, these patients display very high levels
of antibodies against EBV replication proteins whose presence
is a predictive factor for NPC development (Cao et al., 2011;
Chien et al., 2001; Hsu et al., 2009). It is remarkable that these
two defining features are characteristics of M81 and by exten-
sion probably of viruses found in NPC that share a considerable
degree of homology at the protein level. The excessive intake of
substances that activate lytic replication, such as phorbol esters
that are abundant in some food frequently consumed in
Southeast Asia, could further enhance lytic replication in infected
individuals (Davies et al., 1991; Fang et al., 2009; zur Hausen
et al., 1978). Altogether, our data make M81-type viruses prime
suspects, probably in combination with other cocarcinogens
such as smoking and food carcinogens, for the development
of NPC.
Virus species can possess a variable number of subtypes.
Numerous subtypes of influenza A viruses (Webster et al.,
1992) or papillomaviruses (de Villiers et al., 2004) are known.
The definition of a subtype typically rests on sequence heteroge-
neity that might or might not be associated with different proper-
ties of the viruses or their ability to cause disease. The division of
influenza A viruses in subtypes is justified by the absence of
cross-protective immune response between them but also by
the ability of some subtypes to cause serious disease. In the
case of human papillomavirus, only a restricted number of sub-
types cause cervical cancer, and identification of these subtypes
has become an important diagnostic tool in the evaluation of
chronic cervical infection (de Villiers et al., 2004). Herpesviridae
comprise multiple genera and species, but these usually do
not have any subtypes (Roizman and Pellett, 2007). We suggest
to revise this view in EBV’s case and to define M81-type viruses
as a particular subtype with a different cell tropism and a prefer-
ence for lytic replication.
Sequencing of M81 revealed multiple polymorphisms that
distinguish the M81 type from other viral strains. Whole-
genome sequencing methods will deliver additional information
on the sequence of a large number of EBV isolates present in
various tumors and will undoubtedly massively increase the
diversity of virus sequences. The present report suggests
that it will be indispensable to clone these isolates as recombi-
nant viruses in order to understand the impact of polymor-
phisms on the viral functions, in particular in their ability to
induce disease. Indeed, many diseases or tumors associated
with EBV such as chronic active infection, gastric carcinoma,
BL, nasal NK/T cell lymphomas, and peripheral T cell lym-
phomas are mainly seen in particular countries or areas (Rick-
inson and Kieff, 2007; Young and Rickinson, 2004). Our work
suggests that particular alleles in genetic elements encoded
by these viruses contribute to the development of these dis-
eases, but only a genetic approach will allow a full appreciation
of their role.
These observations also suggest that immunization strategies
should take into account the genetic diversity within EBV sub-
types. Indeed, vaccines generated with epitopes from Western
strains might not prevent infection with M81-type strains. Partic-




All cells were routinely cultured in RPMI-1640 medium (Invitrogen) supple-
mented with 10% fetal bovine serum (FBS) (Biochrom), and primary B cells
were supplemented with 20% FBS until establishment. Primary epithelial cells
isolated from normal sphenoidal sinus biopsy material were cultured in kerati-
nocyte serum-free growth medium (KGM-SFM; Invitrogen) as described
previously (Feederle et al., 2007). The ethics committee of the University of
Heidelberg approved the study (approval 392/2005).
Recombinant Viruses
M81 was cloned onto an F-plasmid as previously described (Delecluse et al.,
1998). Viral recombinants were constructed using homologous recombination
either with linear targeting vectors or using chromosomal building (Feederle
et al., 2010). Details on the constructions of the different recombinants used
throughout this study can be found in the Supplemental Information.
Viral Genome Sequencing
The whole-genome map of M81 strain was determined by deep sequencing
with an Illumina HiSeq 2000 and assembled using the GS Reference Mapper
software. The sequences of the ambiguous regions and the repeat regions
were further confirmed using a standard Sanger sequencing method. The
information on the M81 genome is available (GenBank accession number
KF373730).
Plasmids
A BZLF1 expression plasmid (p509) was used for the induction of the lytic
cycle and the expression plasmid coding BALF4 derived from B95-8 (p2354)
was used for gp110 overexpression (Neuhierl et al., 2009). A similar expression
plasmid expressing the M81 BALF4 derived from M81 genome was con-
structed (B809). Expression plasmids encoding the BLLF1 gene (gp350), either
from M81 or B95-8, were constructed into pcDNA3.1 (B702 and B703). The
plasmid B735 contains a minimal CMV promoter controlled by a bidirectional
TetO operator, a tetracycline transactivator protein (Tet-On) driven by a CAG
promoter, the latent EBV origin of replication oriP derived from B95-8, and a
rat CD2 gene driven by SV40 promoter (Bornkamm et al., 2005). The BZLF1
genes from M81 or B95-8 were placed under the tet promoter (B734 and
B733).
BZLF1 Expression in LCLs
LCLs generated with the DBZLF1 virus were stably transfected with these
expression plasmids. Three days postelectroporation, cells carrying the
plasmid were enriched by immunopurification using the monoclonal antibody
OX34 that binds to CD2 positive cells. A secondary antibody coupled to anti-
mouse immunoglobulin G Dynabeads was used to purify CD2-positive cells
(Invitrogen).
Bioinformatics
We compared the protein and DNA sequence of the following virus
isolates: GD1 (accession number AY961628.3), GD2 (accession number
HQ020558.1), HKNPC1 (accession number JQ009376.1), Akata (accession
number KC207813.1), Mutu (accession number KC207814.1), and B95-8
(accession number NC_007605). The alignments and distance trees were
computed with ClustalW version 2.0.12 and the neighbor joining method using
default parameters (Larkin et al., 2007). Distance trees were visualized with the
Drawtree program from Joe Felsenstein’s Phylip package. The phylogenetic
analysis of individual EBV proteins was performed with ClustalW version
2.0.12 for proteins.
Viral Infections
Peripheral blood B cells from several donors were infected with supernatants
from virus producer cell lines at room temperature using various MOIs asell Reports 5, 458–470, October 31, 2013 ª2013 The Authors 467
determined by qPCR or immunostaining with an antibody specific to EBNA2.
Transfer infections were performed as previously described (Shannon-Lowe
et al., 2006).
Electron Microscopy
Infected cell lines, primary cells, or pelleted viruses from 6 ml of viral superna-
tant centrifuged for 2 hr at 30.000 3 g were fixed in 2.5% glutaraldehyde for
20 min at 4C. Further preparation, embedding, and sections were carried
out as described previously (Granato et al., 2008). Ultrathin sections were
examined by electron microscopy (Zeiss).
Immunostaining and Western Blot
Cells were fixed with 4% paraformaldehyde for 20 min at room temperature.
Fixed cells were permeabilized in PBS 0.5% Triton X-100 for 2 min except
for samples stained for viral glycoproteins (gp350/220 and VCA). Cells were
incubated with the first antibody for 30 min, washed in PBS three times, and
incubated with a secondary antibody conjugated to Cy-3 or Alexa 488 for
30 min. Nuclei were counterstained for 1 min with Hoechst 33258 before
embedding in 90% glycerol. Western blots for viral glycoproteins have been
described before (Neuhierl et al., 2002). The antibodies used are listed in the
Supplemental Information.
Southern Blot
Genomic DNA extraction from LCLs, probe preparation and Southern blotting
has been described before (Delecluse et al., 1998). In this study, genomic
DNAs were digested with BamHI and the blots were hybridized with a 32P-
labeled DNA fragment specific to BMRF1 or to an EBV terminal repeat
(Feederle et al., 2009a).
Human Immune System Component Reconstitution in Mice for EBV
Infection
Mice with a reconstituted human immune system were generated by intra-
hepatically injecting newborn NSG-A2 mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl
Tg(HLA-A2.1)1Enge/SzJ) with human hematopoietic progenitor cells (HPCs)
after 1 Gy irradiation (huNSG-A2 mice) (White et al., 2012). Confirmation of
successful reconstitution with human immune cells was obtained by analyzing
the peripheral blood of the animals approximately 12 weeks after HPC
transplantation. The infectious titers of rB95-8 viruses, used for infection of
huNSG-A2 mice, were determined by Raji cell infection as Green Raji units
(GRU) via GFP expression after infection. In all experiments, 1 3 105 GRU of
rB95-8 were used for intraperitoneal infection of huNSG-A2 mice. In one
experiment, we injected with the same number of rM81 or rB95-8 viral
genomes. In the other, we used volumes of rB95-8 and rM81 supernatants
that infected primary B cells with the same efficiency, as determined by an
EBNA2-specific immunostaining. The infected mice were monitored for
5 weeks postinfection and then euthanized, and their tissues were analyzed
by immunohistochemistry. The veterinary office of the canton of Zurich
approved the study (approval 148/2011).
Immunohistochemistry
Organs from the euthanized huNSG-A2 mice were fixed in 10% formalin
and embedded in paraffin, and 3-mm-thin sections were prepared and
immunostained after antigen retrieval (10 mM sodium citrate, 0.05% Tween
20 [pH 6.0]; 98C for 40 min). Bound antibodies were visualized with the
Envision+ Dual link system-HRP (Dako). Pictures were taken with a camera
attached to a light microscope (Axioplan, Zeiss).
Statistics
Statistical evaluation was performed with an unpaired t test using two-tailed
P values and a confidence interval of 95.
For additional details, refer to the Extended Experimental Procedures.
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